[go: up one dir, main page]

AU2001269757A1 - Large-scale recombinant adeno-associated virus (raav) production and purification - Google Patents

Large-scale recombinant adeno-associated virus (raav) production and purification

Info

Publication number
AU2001269757A1
AU2001269757A1 AU2001269757A AU6975701A AU2001269757A1 AU 2001269757 A1 AU2001269757 A1 AU 2001269757A1 AU 2001269757 A AU2001269757 A AU 2001269757A AU 6975701 A AU6975701 A AU 6975701A AU 2001269757 A1 AU2001269757 A1 AU 2001269757A1
Authority
AU
Australia
Prior art keywords
raav
purification
production
associated virus
recombinant adeno
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001269757A
Other languages
English (en)
Inventor
Guang Qu
John Fraser Wright
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Avigen Inc
Original Assignee
Avigen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avigen Inc filed Critical Avigen Inc
Publication of AU2001269757A1 publication Critical patent/AU2001269757A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151Methods of production or purification of viral material

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2001269757A 2000-08-07 2001-06-07 Large-scale recombinant adeno-associated virus (raav) production and purification Abandoned AU2001269757A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09633834 2000-08-07
US09/633,834 US6593123B1 (en) 2000-08-07 2000-08-07 Large-scale recombinant adeno-associated virus (rAAV) production and purification
PCT/US2001/018443 WO2002012455A1 (fr) 2000-08-07 2001-06-07 Production et purification a grande echelle de virus recombinant associe aux adenovurus (raav)

Publications (1)

Publication Number Publication Date
AU2001269757A1 true AU2001269757A1 (en) 2002-02-18

Family

ID=24541304

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001269757A Abandoned AU2001269757A1 (en) 2000-08-07 2001-06-07 Large-scale recombinant adeno-associated virus (raav) production and purification

Country Status (3)

Country Link
US (2) US6593123B1 (fr)
AU (1) AU2001269757A1 (fr)
WO (1) WO2002012455A1 (fr)

Families Citing this family (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070122904A1 (en) * 2000-09-29 2007-05-31 Unisearch Limited Method and apparatus for culturing cells
US20030175688A1 (en) * 2002-03-15 2003-09-18 Rukmini Pennathur-Das Method for the purification and production of oncolytic adenoviruses
US20050009168A1 (en) * 2003-05-12 2005-01-13 Robbins Joan Marie Methods and apparatus for Adeno associated virus purification
DE602004030327D1 (de) 2003-05-21 2011-01-13 Genzyme Corp Verfahren zur herstellung von präparationen rekombinanter aav-virionen, die weitgehend frei von leeren capsiden sind
US20040248826A1 (en) * 2003-06-03 2004-12-09 Alberto Auricchio Treatment of cancer by in vivo gene-transfer induced TIMP-3 expression
US7261882B2 (en) 2003-06-23 2007-08-28 Reagents Of The University Of Colorado Methods for treating neuropathic pain by administering IL-10 polypeptides
MX360727B (es) 2004-06-01 2018-11-14 Genzyme Corp Composiciones y metodos para evitar la agregacion del vector aav.
AU2005322353B2 (en) 2004-12-23 2011-09-01 Medimmune, Llc Non-tumorigenic MDCK cell line for propagating viruses
KR100823157B1 (ko) * 2004-12-30 2008-04-21 재단법인 목암생명공학연구소 재조합 아데노-부속 바이러스를 대량 생산하는 방법
US9198984B2 (en) 2006-04-28 2015-12-01 The Trustees Of The University Of Pennsylvania Scalable production method for AAV
CA2663522C (fr) 2006-09-15 2015-06-02 Medimmune, Llc Lignees cellulaires mdck supportant la croissance virale jusqu'a des titres eleves et procede de bioreacteur les utilisant
EP2031048B2 (fr) 2007-08-31 2019-05-01 The Procter and Gamble Company Composition nettoyante acide liquide pour surfaces dures
EP2039747A1 (fr) 2007-09-17 2009-03-25 The Procter and Gamble Company Procédé pour le traitement d'une surface dure
EP2039748A1 (fr) 2007-09-17 2009-03-25 The Procter and Gamble Company Procédé pour le traitement d'une surface dure inclinée
CN102216450B (zh) 2008-09-24 2014-05-14 米迪缪尼有限公司 培养细胞、增殖和纯化病毒的方法
HUE057606T2 (hu) 2009-05-02 2022-05-28 Genzyme Corp Génterápia neurodegeneratív rendellenességekre
IN2012DN06629A (fr) * 2010-01-28 2015-10-23 Philadelphia Children Hospital
WO2011097447A2 (fr) * 2010-02-04 2011-08-11 Neurologix, Inc. Production de virus recombinant
WO2012048275A2 (fr) 2010-10-08 2012-04-12 Caridianbct, Inc. Procédés et systèmes configurables pour la culture et la récolte de cellules dans un système de bioréacteur à fibres creuses
EP3219313B1 (fr) 2011-04-18 2020-10-28 National Center of Neurology and Psychiatry Particule de libération de médicament et son procédé de fabrication
US20140107321A1 (en) * 2011-05-26 2014-04-17 Dr. Reddy's Laboratories Limited Purification of antibodies
SI2744895T1 (sl) * 2011-09-08 2016-03-31 Uniqure Ip B.V. Odstranitev kontaminantnih virusov iz aav pripravkov
HUE037482T2 (hu) 2013-01-08 2018-08-28 Genzyme Corp Inos-inhibitorok alkalmazása vírushozam növelésére tenyészetben
US11332719B2 (en) 2013-03-15 2022-05-17 The Broad Institute, Inc. Recombinant virus and preparations thereof
SG11201508297YA (en) 2013-04-17 2015-11-27 Genzyme Corp Compositions and methods for treating and preventing macular degeneration
KR102069561B1 (ko) 2013-07-11 2020-01-23 다카라 바이오 가부시키가이샤 외피 비보유 바이러스의 제조 방법
KR102234695B1 (ko) 2014-02-06 2021-04-02 젠자임 코포레이션 황반 변성을 치료하고 예방하기 위한 조성물 및 방법
WO2015191508A1 (fr) 2014-06-09 2015-12-17 Voyager Therapeutics, Inc. Capsides chimériques
US10023846B2 (en) 2014-07-10 2018-07-17 Takara Bio Inc. Production method for non-enveloped virus particles
WO2016049421A1 (fr) 2014-09-26 2016-03-31 Terumo Bct, Inc. Alimentation programmée
MX2017005834A (es) 2014-11-05 2017-11-17 Voyager Therapeutics Inc Polinucleotidos aad para el tratamiento de la enfermedad de parkinson.
SG10202001102XA (en) 2014-11-14 2020-03-30 Voyager Therapeutics Inc Modulatory polynucleotides
SG11201703281RA (en) 2014-11-14 2017-05-30 Voyager Therapeutics Inc Compositions and methods of treating amyotrophic lateral sclerosis (als)
EP3230441A4 (fr) 2014-12-12 2018-10-03 Voyager Therapeutics, Inc. Compositions et méthodes pour la production de scaav
EP3243904A4 (fr) 2015-01-09 2018-06-27 Takara Bio Inc. Procédé de production de particules virales non enveloppées
CN107428799A (zh) 2015-01-13 2017-12-01 阿尔法韦士曼公司 纯化腺相关病毒(AAV)及/或重组腺相关病毒(rAAV)之方法及其梯度和流通式缓冲液
EP3054006A1 (fr) 2015-02-09 2016-08-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Purification de particule de virus adéno-associé recombinant avec une chromatographie à échange d'anions en plusieurs étapes
EP3054007A1 (fr) * 2015-02-09 2016-08-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Purification de particules de virus adéno-associés de recombinaison comprenant une étape de purification par affinité immunologique
EP3368054A4 (fr) 2015-10-28 2019-07-03 Voyager Therapeutics, Inc. Expression régulable au moyen d'un virus adéno-associé (vaa)
PH12018501168B1 (en) * 2015-12-01 2024-05-17 Spark Therapeutics Inc Scalable methods for producing recombinant adeno-associated viral (aav) vector in serum-free suspension cell culture system suitable for clinical use
WO2017160360A2 (fr) 2015-12-11 2017-09-21 The Trustees Of The University Of Pennsylvania Méthode de purification évolutive pour virus adéno-associé 9 (aav9)
EP3992283A1 (fr) 2015-12-11 2022-05-04 The Trustees Of The University Of Pennsylvania Procédé de purification évolutif d'aavrh10
WO2017100674A1 (fr) 2015-12-11 2017-06-15 The Trustees Of The University Of Pennsylvania Procédé de purification évolutif pour virus adéno-associé (aav) 1
EP3387117B1 (fr) 2015-12-11 2022-11-23 The Trustees Of The University Of Pennsylvania Procédé de purification évolutif d'aav8
WO2017112948A1 (fr) * 2015-12-24 2017-06-29 University Of Florida Research Foundation, Inc. Amélioration de la production de vaa par utilisation de cellules qui ont été adaptées à la culture en suspension
JP7364306B2 (ja) 2016-03-31 2023-10-18 スパーク セラピューティクス インコーポレイテッド カラムに基づく高度にスケーラブルなrAAVの製造プロセス
EP3448874A4 (fr) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. Compositions pour le traitement de maladies
EP3448987A4 (fr) 2016-04-29 2020-05-27 Voyager Therapeutics, Inc. Compositions pour le traitement de maladies
WO2017201258A1 (fr) 2016-05-18 2017-11-23 Voyager Therapeutics, Inc. Compositions et méthodes de traitement de la maladie de huntington
JP7066635B2 (ja) 2016-05-18 2022-05-13 ボイジャー セラピューティクス インコーポレイテッド 調節性ポリヌクレオチド
CN109415696A (zh) 2016-05-25 2019-03-01 泰尔茂比司特公司 细胞扩增
EP4219724A3 (fr) 2016-08-23 2023-09-27 Akouos, Inc. Compositions et procédés pour traiter une déficience auditive non associée au vieillissement chez un sujet humain
US11298041B2 (en) 2016-08-30 2022-04-12 The Regents Of The University Of California Methods for biomedical targeting and delivery and devices and systems for practicing the same
CN110325203A (zh) 2017-01-07 2019-10-11 西莱克塔生物科技公司 与合成纳米载体偶联的免疫抑制剂的模式化给药
CN110612344B (zh) 2017-03-31 2023-09-12 泰尔茂比司特公司 细胞扩增
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
CA3061652A1 (fr) 2017-05-05 2018-11-08 Voyager Therapeutics, Inc. Compositions et methodes de traitement de la sclerose laterale amyotrophique (sla)
AU2018261003A1 (en) 2017-05-05 2019-11-14 Voyager Therapeutics, Inc. Compositions and methods of treating Huntington's Disease
CA3066358A1 (fr) 2017-06-07 2018-12-13 Spark Therapeutics, Inc. Agents d'activation destines a la transfection de cellules et/ou la production de vecteur raav ameliorees
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
PE20200737A1 (es) * 2017-06-30 2020-07-23 Spark Therapeutics Inc Metodos de purificacion de columna de vector aav
US11497576B2 (en) 2017-07-17 2022-11-15 Voyager Therapeutics, Inc. Trajectory array guide system
US11512327B2 (en) 2017-08-03 2022-11-29 Voyager Therapeutics, Inc. Compositions and methods for delivery of AAV
AU2018338728B2 (en) 2017-09-29 2025-01-02 Centre National De La Recherche Scientifique (Cnrs) Rescue of central and peripheral neurological phenotype of Friedreich's Ataxia by intravenous delivery
WO2019079242A1 (fr) 2017-10-16 2019-04-25 Voyager Therapeutics, Inc. Traitement de la sclérose latérale amyotrophique (sla)
TW202413649A (zh) 2017-10-16 2024-04-01 美商航海家醫療公司 肌萎縮性脊髓側索硬化症(als)之治療
SG11202006232SA (en) * 2017-12-29 2020-07-29 Baxalta Inc Adeno-associated virus purification methods
EP3762500A1 (fr) 2018-03-06 2021-01-13 Voyager Therapeutics, Inc. Génomes aav partiels auto-complémentaires fabriqués par des cellules d'insectes
US12319929B2 (en) 2018-05-15 2025-06-03 Voyager Therapeutics, Inc. Compositions and methods for the treatment of Parkinson's disease
US20210207167A1 (en) 2018-05-16 2021-07-08 Voyager Therapeutics, Inc. Aav serotypes for brain specific payload delivery
EP3793615A2 (fr) 2018-05-16 2021-03-24 Voyager Therapeutics, Inc. Évolution dirigée
AU2019285186B2 (en) 2018-06-14 2025-05-29 Regenxbio Inc. Anion exchange chromatography for recombinant AAV production
CN112567035A (zh) 2018-07-02 2021-03-26 沃雅戈治疗公司 肌萎缩侧索硬化症及脊髓相关病症的治疗
EP3826719A1 (fr) 2018-07-24 2021-06-02 Voyager Therapeutics, Inc. Systèmes et méthodes de production de formulations de thérapie génique
CN109182281B (zh) * 2018-08-31 2022-08-02 首都医科大学 处理腺相关病毒的方法及试剂盒
CN121160803A (zh) 2018-09-28 2025-12-19 沃雅戈治疗公司 具有经工程化改造的启动子的共济蛋白表达构建体及其使用方法
US20210348242A1 (en) 2018-10-04 2021-11-11 Voyager Therapeutics, Inc. Methods for measuring the titer and potency of viral vector particles
US20220064671A1 (en) 2019-01-18 2022-03-03 Voyager Therapeutics, Inc. Methods and systems for producing aav particles
CA3138525A1 (fr) 2019-04-28 2020-11-05 Selecta Biosciences, Inc. Methodes de traitement de sujets presentant une immunite preexistante a des vecteurs de transfert viraux
WO2020223274A1 (fr) 2019-04-29 2020-11-05 Voyager Therapeutics, Inc. Système et procédé pour la production de cellules d'insectes infectées par baculovirus (ceib) dans les bioréacteurs
JP7539420B2 (ja) * 2019-06-28 2024-08-23 武田薬品工業株式会社 アデノ随伴ウイルスの精製方法
EP4010465A1 (fr) 2019-08-09 2022-06-15 Voyager Therapeutics, Inc. Milieu de culture cellulaire destiné à être utilisé dans la production de produits de thérapie génique dans des bioréacteurs
TW202122582A (zh) 2019-08-26 2021-06-16 美商航海家醫療公司 病毒蛋白之控制表現
WO2021124152A1 (fr) 2019-12-19 2021-06-24 Pfizer Inc. Compositions et procédés de transfection d'acide nucléique à l'aide de polymères cationiques et de stabilisants
MX2022010050A (es) 2020-02-21 2022-09-05 Akouos Inc Composiciones y metodos para tratar deficiencia auditiva no asociada con la edad en un sujeto humano.
EP3919613B1 (fr) * 2020-06-05 2024-08-07 Sartorius BIA Separations d.o.o. Purification améliorée de virus adéno-associés pour l'élimination plus efficace d'adn contaminants
US20230295656A1 (en) 2020-08-06 2023-09-21 Voyager Therapeutics, Inc. Cell culture medium for use in producing gene therapy products in bioreactors
WO2022043926A1 (fr) * 2020-08-31 2022-03-03 Intas Pharmaceuticals Ltd. Processus de préparation d'une particule de virus adéno-associé recombinant
EP4217087A2 (fr) * 2020-09-23 2023-08-02 Codiak BioSciences, Inc. Procédé de préparation de vésicules extracellulaires
AR123776A1 (es) 2020-10-15 2023-01-11 Hoffmann La Roche Construcciones de ácido nucleico para la activación simultánea de genes
CA3197730A1 (fr) 2020-10-15 2022-04-21 F. Hoffman-La Roche Ag Constructions d'acide nucleique pour transcription de va-arn
JP7683230B2 (ja) * 2021-01-27 2025-05-27 東ソー株式会社 アデノ随伴ウイルスの精製方法
WO2022187548A1 (fr) 2021-03-03 2022-09-09 Voyager Therapeutics, Inc. Expression régulée de protéines virales
US20240141377A1 (en) 2021-03-03 2024-05-02 Voyager Therapeutics, Inc. Controlled expression of viral proteins
WO2023198685A1 (fr) 2022-04-13 2023-10-19 F. Hoffmann-La Roche Ag Procédé de détermination de génomes d'aav
GB202205514D0 (en) * 2022-04-13 2022-05-25 Freeline Therapeutics Ltd Mechanical lysis
JP2025517987A (ja) 2022-05-23 2025-06-12 エフ. ホフマン-ラ ロシュ アーゲー Aav粒子血清型およびaav粒子負荷状態の識別のためのラマンベースの方法
CA3258165A1 (fr) 2022-06-03 2023-12-07 F. Hoffmann-La Roche Ag Procédé de production de particules de virus associé aux adénovirus (vaa) recombinées
AR129895A1 (es) 2022-07-14 2024-10-09 Hoffmann La Roche Método para producir partículas de aav recombinantes
WO2024054983A1 (fr) 2022-09-08 2024-03-14 Voyager Therapeutics, Inc. Expression controlée de protéines virales
IL318766A (en) 2022-09-12 2025-04-01 Hoffmann La Roche Method for separating full and empty AAV particles
IL322001A (en) 2023-02-07 2025-09-01 Hoffmann La Roche Method for detecting antibodies to anti-AAV particles
EP4683676A1 (fr) 2023-03-21 2026-01-28 F. Hoffmann-La Roche AG Méthode destinée à produire des préparations de particules aav recombinantes
WO2024206396A1 (fr) * 2023-03-28 2024-10-03 Biogen Ma Inc. Procédés de production de virus adéno-associé recombiné (raav)
CN120981561A (zh) 2023-04-03 2025-11-18 建新公司 细胞溶解装置及其使用方法
WO2024233791A1 (fr) 2023-05-11 2024-11-14 Seelos Therapeutics, Inc. Méthodes de traitement de troubles neurodégénératifs
WO2025168663A1 (fr) 2024-02-09 2025-08-14 F. Hoffmann-La Roche Ag Procédé de production de particules virales adéno-associées recombinées
WO2025252480A1 (fr) 2024-06-07 2025-12-11 F. Hoffmann-La Roche Ag Procédé de purification d'adn plasmidique
CN119639868B (zh) * 2025-02-20 2025-09-23 南京鸿明生物科技有限公司 Aav三代测序的基因抽提方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837520A (en) 1995-03-07 1998-11-17 Canji, Inc. Method of purification of viral vectors
US6040183A (en) * 1995-06-07 2000-03-21 University Of North Carloina At Chapel Hill Helper virus-free AAV production
JPH11511326A (ja) * 1995-08-30 1999-10-05 ジエンザイム コーポレイション アデノウィルスおよびaavの精製
US6566118B1 (en) * 1997-09-05 2003-05-20 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6995006B2 (en) * 1997-09-05 2006-02-07 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
EP1009808B1 (fr) * 1997-09-05 2012-12-05 Genzyme Corporation Procedes de generation de preparations de vecteurs aav recombinants dont le titre est eleve et qui sont exemptes de "helper"virus
US6146874A (en) 1998-05-27 2000-11-14 University Of Florida Method of preparing recombinant adeno-associated virus compositions
US6416992B1 (en) 1998-10-13 2002-07-09 Avigen, Inc. Compositions and methods for producing recombinant adeno-associated virus
US6221349B1 (en) * 1998-10-20 2001-04-24 Avigen, Inc. Adeno-associated vectors for expression of factor VIII by target cells

Also Published As

Publication number Publication date
US6593123B1 (en) 2003-07-15
WO2002012455A1 (fr) 2002-02-14
US20030207439A1 (en) 2003-11-06

Similar Documents

Publication Publication Date Title
AU2001269757A1 (en) Large-scale recombinant adeno-associated virus (raav) production and purification
AU2001257611A1 (en) Polynucleotides for use in recombinant adeno-associated virus virion production
AU2001287720A1 (en) Host cells for packing a recombinant adeno-associated virus (RAAV), method for the production and use thereof
AU2002211686A1 (en) Bandage using molecular sieves
AU2002328128A1 (en) Mutant recombinant adeno-associated viruses related applications
AU2002360291A1 (en) Adeno-associated virus (aav) serotype 8 sequences
AU4428299A (en) Molecular sieve adsorbent for gas purification and preparation thereof
AU2001273599A1 (en) Glass ceramic composites
AU2001297896A1 (en) Mutant proteins, high potency inhibitory antibodies and fimch crystal structure
GB0017720D0 (en) Modified virus
AU2001282625A1 (en) Stream decoder
AU2001240018A1 (en) Adeno-associated viral compositions and methods
AU5330500A (en) Improved stream switching system
AU5827000A (en) Viral il-10 uses
AU2003272868A1 (en) Method for large-scale production, isolation, purification and the uses of multi-type recombinant adeno-associated virus vectors
AU2002220416A1 (en) Oncolytic virus
AU2001281464A1 (en) Recombinant proteins containing repeating units
AU6551800A (en) Dinucleoside 5',5'-tetraphosphates as inhibitors of viral reverse transcriptasesand viruses
AU2002224845A1 (en) Viral expression system
AU5601700A (en) Stream switching system
AU3937101A (en) Purified polynucleotide sequences of plants and yeast coding for proteins interacting with the products of geminivirus genome
AU2001271444A1 (en) Purification means
AU2001274563A1 (en) Novel polypeptide and its dna
AU2002316348A1 (en) Chimeric capsid proteins and uses thereof
AU5300999A (en) Novel protein, gene encoding the same and utilization thereof